Bionano Genomics Stock Today
| BNGO Stock | USD 0.76 0.03 3.66% |
Performance0 of 100
| Odds Of DistressOver 85
|
Bionano Genomics is selling at 0.7611 as of the 25th of April 2024; that is -3.66 percent down since the beginning of the trading day. The stock's open price was 0.79. Bionano Genomics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Bionano Genomics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of January 2024 and ending today, the 25th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 21st of August 2018 | Category Healthcare | Classification Health Care |
Bionano Genomics, Inc. provides genome analysis software solutions. The company was founded in 2003 and is headquartered in San Diego, California. Bionano Genomics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. The company has 61.23 M outstanding shares of which 5.27 M shares are currently shorted by private and institutional investors with about 3.69 trading days to cover. More on Bionano Genomics
Moving together with Bionano Stock
| 0.7 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
| 0.83 | DRMA | Dermata Therapeutics Financial Report 9th of May 2024 | PairCorr |
Moving against Bionano Stock
| 0.78 | YS | YS Biopharma | PairCorr |
| 0.71 | FUSN | Fusion PharmaceuticalsInc Financial Report 9th of May 2024 | PairCorr |
| 0.7 | DSGN | Design Therapeutics Financial Report 14th of May 2024 | PairCorr |
| 0.67 | HCM | HUTCHMED DRC | PairCorr |
| 0.65 | ELYM | Eliem Therapeutics | PairCorr |
| 0.65 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.64 | XFOR | X4 Pharmaceuticals Earnings Call This Week | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 14th of May 2024
Bionano Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Bionano Genomics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Bionano Genomics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO, Director | Erik Holmlin | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Life Sciences Tools & Services, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Bionano Genomics report their recommendations after researching Bionano Genomics' financial statements, talking to executives and customers, or listening in on Bionano Genomics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Bionano Genomics. The Bionano consensus assessment is calculated by taking the average forecast from all of the analysts covering Bionano Genomics. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Bionano Genomics' liquidity, profitability, solvency, and operating efficiency, Bionano Genomics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in May. Financial strength of Bionano Genomics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bionano Genomics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Bionano Genomics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Bionano Genomics' financial leverage. It provides some insight into what part of Bionano Genomics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bionano Genomics (BNGO) is traded on NASDAQ Exchange in USA. It is located in 9540 Towne Centre Drive, San Diego, CA, United States, 92121 and employs 344 people. Bionano Genomics is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 48.64 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bionano Genomics's market, we take the total number of its shares issued and multiply it by Bionano Genomics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Bionano Genomics conducts business under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 61.23 M outstanding shares of which 5.27 M shares are currently shorted by private and institutional investors with about 3.69 trading days to cover.
Bionano Genomics currently holds about 187.34 M in cash with (129.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.65.
Check Bionano Genomics Probability Of Bankruptcy
Ownership AllocationBionano Genomics retains a total of 61.23 Million outstanding shares. Almost 88.0 percent of Bionano Genomics outstanding shares are held by general public with 0.49 (percent) owned by insiders and only 11.96 % by other corporate entities. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Bionano Ownership Details
Bionano Stock Price Odds Analysis
Contingent on a normal probability distribution, the odds of Bionano Genomics jumping above the current price in 90 days from now is close to 99%. The Bionano Genomics probability density function shows the probability of Bionano Genomics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 3.2585 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Bionano Genomics will likely underperform. Additionally, bionano Genomics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Bionano Genomics to move above the current price in 90 days from now is close to 99 (This Bionano Genomics probability density function shows the probability of Bionano Stock to fall within a particular range of prices over 90 days) .
Bionano Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Bionano Genomics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Bionano Genomics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bionano Genomics' value.| Instituion | Recorded On | Shares | |
| Gsa Capital Partners Llp | 2023-12-31 | 86.9 K | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 82.3 K | |
| Archford Capital Strategies, Llc | 2023-12-31 | 69.6 K | |
| Jane Street Group, Llc | 2023-12-31 | 68.6 K | |
| Engineers Gate Manager Lp | 2023-12-31 | 60.2 K | |
| Fmr Inc | 2023-12-31 | 53.6 K | |
| Two Sigma Securities, Llc | 2023-12-31 | 49.4 K | |
| Susquehanna International Group, Llp | 2023-12-31 | 42 K | |
| Headlands Technologies Llc | 2023-12-31 | 38 K | |
| Vanguard Group Inc | 2023-12-31 | 1.9 M | |
| Gmt Capital Corp | 2023-12-31 | 530.3 K |
Bionano Genomics Historical Income Statement
Bionano Genomics Income Statement is one of the three primary financial statements used for reporting Bionano's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Bionano Genomics revenue and expense. Bionano Genomics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Bionano Genomics' Other Operating Expenses is very stable compared to the past year. As of the 25th of April 2024, Research Development is likely to grow to about 56.7 M, while Net Interest Income is likely to drop (1.9 M). View More FundamentalsBionano Stock Against Markets
Picking the right benchmark for Bionano Genomics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Bionano Genomics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Bionano Genomics is critical whether you are bullish or bearish towards Bionano Genomics at a given time. Please also check how Bionano Genomics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Bionano Genomics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Aroon Oscillator Now
Aroon OscillatorAnalyze current equity momentum using Aroon Oscillator and other momentum ratios |
| All Next | Launch Module |
Bionano Genomics Corporate Directors
Bionano Genomics corporate directors refer to members of a Bionano Genomics board of directors. The board of directors generally takes responsibility for the Bionano Genomics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Bionano Genomics' board members must vote for the resolution. The Bionano Genomics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Albert Luderer | Independent Director | Profile | |
| Kristiina Vuori | Independent Director | Profile | |
| Darren Cai | Independent Director | Profile | |
| Christopher Twomey | Independent Director | Profile |
How to buy Bionano Stock?
Before investing in Bionano Genomics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Bionano Genomics. To buy Bionano Genomics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Bionano Genomics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Bionano Genomics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Bionano Genomics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Bionano Genomics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Bionano Genomics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Bionano Stock please use our How to Invest in Bionano Genomics guide.
Already Invested in Bionano Genomics?
The danger of trading Bionano Genomics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Bionano Genomics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Bionano Genomics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Bionano Genomics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Bionano Genomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bionano Genomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bionano Genomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bionano Genomics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bionano Genomics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.Note that the Bionano Genomics information on this page should be used as a complementary analysis to other Bionano Genomics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for Bionano Stock analysis
When running Bionano Genomics' price analysis, check to measure Bionano Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bionano Genomics is operating at the current time. Most of Bionano Genomics' value examination focuses on studying past and present price action to predict the probability of Bionano Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bionano Genomics' price. Additionally, you may evaluate how the addition of Bionano Genomics to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
Is Bionano Genomics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.81) | Revenue Per Share 1.058 | Quarterly Revenue Growth 0.305 | Return On Assets (0.33) | Return On Equity (1.35) |
The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionano Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.